Does long-term culture favor normal clonogenic cells from interferon-treated patients with chronic myelogenous leukemia?

Leukemia

Volumn 13, Issue , 1999, Pages 55-64

  Pasternak, G ^a   Schultheis, B ^a   Heissig, B ^a   Horner S ^a   Sick, C ^a   Hehlmann, R ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

BCR ABL; Chronic myelogenous leukemia (CML); Colony forming cells (CFC); Fluorescent in situ hybridization (FISH); Interferon; Long term culture (LTC)

Indexed keywords

INTERFERON;

CELL CULTURE; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLONOGENIC ASSAY; COLONY FORMING CELL; CONFERENCE PAPER; CONTROLLED STUDY; CULTURE MEDIUM; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; INTERPHASE; LEUKOCYTE COUNT; MONONUCLEAR CELL; ONCOGENE; PRIORITY JOURNAL; STEM CELL; STROMA CELL;

EID: 0033005333     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2401288     Document Type: Review

References (60)

1. Udomsakdi C, Eaves CJ, Swolin B, Reid DS, Barnett MJ, Eaves AC. Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc Natl Acad Sci USA 1992; 89: 6192-6196.
2. Verfaillie CM, Miller WJ, Boylan K, McGlave PB. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 1992; 79: 1003-1010.
3. Eaves AC, Cashman JD, Gaboury LA, Kalousek DK, Eaves CJ. Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells. Proc Natl Acad Sci USA 1986; 83: 5306-5310.
4. Whang-Peng J, Canellos GP, Carbone PP, Tjio JH. Clinical implications of cytogenetic variants in chronic myelocytic leukemia (CML). Blood 1968; 32: 755-766.
5. Chervenick PA, Ellis LD, Pan SF, Lawson AL. Human leukemic cells: in vitro growth of colonies containing the Philadelphia (Ph1) chromosome. Science 1971; 174: 1134-1136.
6. Finney R, McDonald GA, Baikie AG, Douglas AS. Chronic granulocytic leukaemia with Ph1 negative cells in bone marrow and a 10-year remission after busulphan hypoplasia. Br J Haematol 1972; 23: 283-288.
7. Smalley RV, Vogel J, Huguley CM, Miller D. Chronic granulocytic leukemia: cytogenetic conversion of the bone marrow with cyclespecific chemotherapy. Blood 1977; 50: 107-113.
8. + chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol). Blood 1979; 53: 375-395.
9. + chronic myelogenous leukemia and effects S63 of intensive treatment. Blood 1982; 59: 793-808.
10. Carella AM, Podestà M, Frassoni F, Pungolino E, Pollicardo N, Raffo MR, Ferrero R, Benvenuto F, Figari O, Giordano D, Lercari G, Carlier P, Valbonesi M, Vitale V, Parodi M, Gallamini A, Saglio G, Marmont AM. Selective overshoot of Ph-negative blood hemopoietic cells after intensive idarubicin-containing regimen and their repopulating capacity after reinfusion. Stem Cells 1993; 11 (Suppl 3): 67-72.
11. Carella AM, Podestà M, Frassoni F, Raffo MR, Pollicardo N, Pungolino E, Vimercati R, Sessarego M, Parodi C, Rabitti C, Ferrero R, Benvenuto F, Figari O, Carlier P, Levcasic G, Valbonesi M, Vitale V, Giordano D, Pierluigi D, Nati S, Guerracio A, Rosso C, Saglio G. Collection of ‘normal’ blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant 1993; 12: 267-271.
12. Carlo-Stella C, Mangoni L, Piovani G, Garau D, Almici C, Rizzoli V. Identification of Philadelphia-negative granulocyte-macrophage colony-forming units generated by stroma-adherent cells from chronic myelogenous leukemia patients. Blood 1994; 83: 1373-1380.
13. Sirard C, Lapidot T, Vormoor J, Cashman JD, Doedens M, Murdoch B, Jamal N, Messner H, Addey L, Minden M, Laraya P, Keating A, Eaves A, Lansdorp PM, Eaves CJ, Dick JE. Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. Blood 1996; 87: 1539-1548.
14. Hughes TP, Grigg A, Szer J, Ho J, Ma D, Dale BM, Green RM, Norman JE, Sage RE, Herrmann R, Cannell P, Schwarer AP, Taylor K, Atkinson K, Arthur C. Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control. Br J Haematol 1997; 96: 635-640.
15. Tkachuk DC, Westbrook CA, Andreeff M, Donlon TA, Cleary ML, Suryanarayan K, Homge M, Redner A, Gray J, Pinkel D. Detection of bcr-abl fusion in chronic myelogenous leukemia by in situ hybridization. Science 1990; 250: 559-562.
16. + cells isolated from the mobilized peripheral blood of a-interferon-resistant or-intolerant patients with chronic myeloid leukemia. Blood 1996; 87: 4348-4357.
17. + cells circulating in the blood of chronic phase chronic myeloid leukemia patients. Leukemia 1997; 11: 1486-1492.
18. Sinclair PB, Green AR, Grace C, Nacheva EP. Improved sensitivity of BCR-ABL detection: a triple probe three-color fluorescence in situ hybridization system. Blood 1997; 90: 1395-1402.
19. Haferlach T, Winkemann M, Nickenig C, Meeder M, Ramm-Petersen L, Schoch R, Nickelsen M, Weber-Matthiesen K, Schlegelberger B, Schoch C, Gassmann W, Löffler H. Which compartments are involved in Philadelphia chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May-Grünwald staining and fluorescence in situ hybridization techniques. Br J Haematol 1997; 97: 99-106.
20. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alphaA in chronic myelogenous leukemia. New Engl J Med 1986; 314: 1065-1069.
21. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Int Med 1991; 114: 532-538.
22. Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R. Persistence of dormant leukemic progenitors during interferoninduced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest 1994; 94: 1383-1389.
23. Kantarjian HM, Talpaz M, Kurzrock R, Keating MJ, McCredie KB, Gutterman J, Freireich EJ. Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia. Acta Haematol 1987; 78 (Suppl. 1): 70-74.
24. Kantarjian H, Smith T, O’Brien S, Beran M, Pierce S, Talpaz M and the Leukemia Service. Prolonged survival in chronic myelogenous leukemia following cytogenetic response to alpha interferon therapy. Ann Int Med 1995; 122: 254-261.
25. Niederle N, Kloke O, Osieka R, Wandl U, Opalka B, Schmidt CG. Interferon alfa-2b in the treatment of chronic myelogenous leukemia. Semin Oncol 1987; 14: 29-35.
26. Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inverardi D, Bernasconi P, Mancini M, Donti E, Grignani F, Bernasconi C, Dianzani F, Mandelli F. Interferon alpha-2b therapy for Ph9-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 1988; 72: 642-647.
27. Opalka B, Wandl UB, Becher R, Kloke O, Nagel-Hiemke M, Moritz T, Beer U, Seeber S, Niederle N. Minimal residual disease in patients with chronic myelogenous leukemia undergoing longterm treatment with recombinant interferon a-2b alone or in combination with interferon-g. Blood 1991; 78: 2188-2193.
28. Malinge M-C, Mahon FX, Delfau MH, Daheron L, Kitzis A, Guilhot F, Tanzer J, Grandchamp B. Quantitative determination of the hybird Bcr-Abl RNA in patients with chronic myelogenous leukaemia under interferon therapy. Br J Haematol 1992; 82: 701-707.
29. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, Arthur DD, Powell B, Gottlieb A, Peterson BA, Rai K, Testa JR, LeBeau M, Tantravahi R, Bloomfield CD. Prolonged subcutaneous administration of recombinant a2b interferon in patients with previously untreated Philadelphia chromosome-positive chronicphase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 1993; 82: 2975-2984.
30. Tura S, for the Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl J Med 1994; 330: 820-825.
31. Hehlmann H, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Hochhaus A, Heinze B, Georgii A, Bartram CR, Grisserammer M, Bergmann L, Essers U, Falge C, Queisseh U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg UR, Käbisch A, Nerl C, Zimmermann R, Meuret G, Tichelli A, Kanz L, Tigges FJ, Schmid L, Brockhaus W, Tobler A, Reiter A, Perker M, Emmerich B, Verpoort K, Zankovich R, von Wussow P, Prümmer O, Thiele J, Buhr T, Ansari H and the German CML Study Group. Randomized comparison of interferonalpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84: 4064-4077.
32. Hehlmann R. Chronic myelogenous leukemia: does interferon alpha prolong life? Leukemia 1996; 10: 193-196.
33. Allan NC, Richards SM, Shepherd PCA on behalf of the UK Medical Research Council’s Working Parties for Therapeutic Trials in Adult Leukaemia. UK Medical Research Council randomised, multicentre trial of intereron-a n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392-1397.
34. Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, Mizoguchi H, Miyawaki S, Tsubaki K, Miura Y, Omine M, Kobayashi T, Naoe T, Ohshima T, Hirashima K, Ohtake S, Takahashi I, Morishima Y, Naito K, Asou N, Tanimoto M, Sakuma A, Yamada K and the Kouseisho Leukemia Study Group. A randomized trial comparing interferon-a with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86: 906-916.
35. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau J-L, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall J-F, Tanzer J for the French Chronic Myeloid Leukemia Study Group. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. New Engl J Med 1997; 337: 223-229.
36. The Benelux CML Study Group. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferona2b for chronic myeloid leukemia. Blood 1998; 91: 2713-2721.
37. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1987; 328: 342-344.
38. Dowding C, Guo AP, Osterholz J, Sichowski M, Goldman JM, Gordon MY. Interferon alpha overrides the deficient adhesion of CML primitive progenitor cells to bone marrow stromal cells. Blood 1991; 78: 499-505.
39. Upadhyaya G, Guba SC, Sih SA, Feinberg AP, Talpaz M, Kantarjian HM, Deisseroth AB, Emerson SG. Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest 1991; 88: 2131-2136.
40. Verfaillie CM, McCarthy JB, McGlave PB. Mechanisms underlying the abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to basement membrane components laminin and collagen type IV. J Clin Invest 1992; 90: 1232-1241.
41. Verfaillie CM, Hurley R, Lundell BI, Zhao C, Bhatia R. Integrinmediated regulation of hematopoiesis: do BCR/ABL induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors? Acta Haematol 1997; 97: 40-52.
42. Bhatia R, Wayner EA, McGlave PB, Verfaillie CM. Interferon-a restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired b1 integrin receptor function. J Clin Invest 1994; 94: 384-391.
43. Lundell BI, McCarthy JB, Kovach NL, Verfaillie CM. Activationdependent a5b1 integrin-mediated adhesion to fibronectin decreases proliferation of chronic myelogenous leukemia progenitors and K562 cells. Blood 1996; 87: 2450-2458.
44. Bazzoni G, Carlesso N, Griffin JD, Hemler ME. BCR/ABL expression stimulates integrin function in hematopoietic cell lines. J Clin Invest 1996; 98: 521-528.
45. Krämer A, Willer A, Hochhaus A, Saussele S, Hallek M, Hehlmann R. BCR/ABL stimulates adhesion of myeloid cells to fibronectin by increased expression of a5b1 integrins. J Mol Med 1997; 75: Abstr. B151.
46. Ghaffari S, Dougherty GJ, Eaves AC, Eaves CJ. Diverse effects of anti-CD44 antibodies on the stromal cell-mediated support of normal but not leukaemic (CML) haemopoiesis in vitro. Br J Haematol 1997; 97: 22-28.
47. Skorski T, Nieborowska-Skorska M, Wlodarski P, Wasik M, Trotta R, Kanakaraj P, Salomoni P, Antonyak M, Martinez R, Majewski M, Wong A, Perussia B, Calabretta B. The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing. Blood 1998; 91: 406-418.
48. Coulombel L, Kalousek DK, Eaves CJ, Gupta CM, Eaves AC. Longterm marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosomepositive chronic myelogenous leukemia. New Engl J Med 1983; 308: 1493-1498.
49. Dubé ID, Kalousek DK, Coulombel L, Gupta CM, Eaves CJ, Eaves AC. Cytogenetic studies in early myeloid progenitor compartments in Ph9-positive chronic myeloid leukemia. II Long-term culture reveals the persistence of Ph9-negative progenitors in treated as well as newly diagnosed patients. Blood 1984; 63: 1172-1177.
50. Hogge DE, Coulombel L, Kalousek DK, Eaves CJ, Eaves AC. Nonclonal hematopoietic progenitors in a G6PD heterozygote with chronic myelogenous leukemia revealed after long-term marrow culture. Am J Hematol 1987; 24: 389-394.
51. Udomsakdi C, Eaves CJ, Lansdorp PM, Eaves AC. Phenotypic heterogeneity of primitive leukemic hematopoietic cells in patients with chronic myeloid leukemia. Blood 1992; 80: 2522-2530.
52. Verfaillie CM, Bhatia R, Miller W, Mortari F, Roy V, Burger S, McCullough J, Stieglbauer K, Dewald G, Heimfeld S, Miller JS, McGlave PB. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most earlychronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood 1996; 87: 4770-4779.
53. Brandwein JM, Dubé ID, Laraya P, Keating A. Maintenance of Philadelphia-chromosome-positive progenitors in long-term marrow cultures from patients with advanced chronic myeloid leukemia. Leukemia 1992; 6: 556-561.
54. Leemhuis T, Leibowitz D, Cox G, Silver R, Srour EF, Tricot G, Hoffman R. Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow. Blood 1993; 81: 801-807.
55. Pasternak G, Pasternak L. Persistence of bcr-abl mRNA-expressing cells in long-term cultures established from chronic myeloid leukemic bone marrow or blood. Ann Hematol 1994; 68: 9-14.
56. Agarwal R, Doren S, Hicks B, Dunbar CE. Long-term culture of chronic myelogenous leukemia marrow cells on stem cell factordeficient stroma favors benign progenitors. Blood 1995; 85: 1306-1312.
57. Petzer AL, Eaves CJ, Barnett MJ, Eaves AC. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood 1997; 90: 64-69.
58. Thijsen SFT, Van Oostveen JW, Schuurhuis GJ, Theijsmeijer AP, Oudejans CBM, Van Wijk IJ, Langenhuijsen MMAC, Ossenkoppele GJ. Hypersensitivity of bcr-abl-positive progenitors to hyperthermia in patients with chronic myeloid leukemia. Leukemia 1997; 11: 1762-1768.
59. Cornelissen JJ, Wognum AW, Ploemacher RE, Frassoni F, Wagemaker G, Hagemeijer A, Löwenberg B. Efficient long-term maintenance of chronic myeloid leukemia cobblestone area forming cells on a murine stromal cell line. Leukemia 1997; 11: 126-133.
60. Sutherland HJ, Lansdorp PM, Henkelman DH, Eaves AC, Eaves CJ. Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. Proc Natl Acad Sci USA 1990; 87: 3584-3588.